A biostatistician by training, Chris is an executive leader with the technical and business experience required to lead in the clinical research industry. He held executive and senior leadership roles before MMS, including management of biometrics operations as well as oversight of key customer accounts. His key strengths include his statistical and data expertise, building and maintaining required operational delivery models to ensure quality delivery, implementing effective governance to ensure successful client collaborations and relationships, and providing statistical consultation.  Throughout his career, Chris has been a statistical lead for hundreds of clinical studies, served as a voting member on data monitoring committees, and guided the statistical strategy for regulatory submissions.

I’m grateful to work at a company with such a strong company culture that cares about its colleagues. Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.
Chris Schoonmaker
Chief Operating Officer

As Chief Operating Officer, Chris has global responsibility for operations across all MMS service lines globally as well as business strategies for growth. Chris is responsible for driving corporate operational excellence, including talent planning, productivity improvements and cost management across the organization.

Chris received his Master of Public Health in Epidemiology and Biostatistics from Boston University.

Suggested For You

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development